Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Free Cash Flow (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Free Cash Flow for 13 consecutive years, with $19.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow fell 26.6% year-over-year to $19.4 million, compared with a TTM value of -$13.4 million through Dec 2025, down 156.59%, and an annual FY2025 reading of -$13.4 million, down 156.59% over the prior year.
  • Free Cash Flow was $19.4 million for Q4 2025 at Tandem Diabetes Care, up from $4.2 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $34.4 million in Q3 2022 and bottomed at -$22.4 million in Q1 2023.
  • Average Free Cash Flow over 5 years is $5.9 million, with a median of $9.1 million recorded in 2022.
  • The sharpest move saw Free Cash Flow tumbled 282.88% in 2023, then soared 480.05% in 2024.
  • Year by year, Free Cash Flow stood at $13.9 million in 2021, then plummeted by 57.51% to $5.9 million in 2022, then plummeted by 217.55% to -$6.9 million in 2023, then skyrocketed by 480.05% to $26.4 million in 2024, then fell by 26.6% to $19.4 million in 2025.
  • Business Quant data shows Free Cash Flow for TNDM at $19.4 million in Q4 2025, $4.2 million in Q3 2025, and -$15.7 million in Q2 2025.